Skip to main content

Table 1 Patient characteristics

From: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

Characteristic

Overall

Worsening

PRMS

SPMS

  

RRMS

  

At baseline

    

 Patients enrolled,a n (%)

509 (100.0)

81 (15.9)

33 (6.5)

395 (77.6)

 Mean age, years (range)

46 (19–68)

40 (19–63)

47 (30–64)

47 (25–68)

 Women,%

67.6

77.8

54.5

66.6

 White,%

88.6

85.2

87.9

89.4

 History of MS, n

506

80

32

394

  Median EDSS score (range)

6.0 (0.0–9.0)

4 (1.0–8.0)

6.0 (1.5–8.5)

6.5 (0.0–9.0)

  Median years since onset (range)

11.8 (0.4–45.3)

8.0 (0.4–29.2)

11.5 (0.6–34.5)

13.0 (0.6–45.3)

  Median years since diagnosis (range)

8.6 (0.0–39.9)

4.8 (0.0–24.6)

7.3 (0.1–26.5)

9.3 (0.1–39.9)

  Median years since most recent relapse (range)

0.4 (0.0–20.3)

0.2 (0.0–2.4)

0.2 (0.0–4.6)

0.5 (0.0–20.3)

  Patients with no prior treatment for MS, n (%)

16 (3.1)

3 (3.7)

2 (6.1)

11 (2.8)

  Women with regular menses, n (%)

128 (37.2)

34 (54.0)

7 (38.9)

87 (33.1)

 Cardiac, n

505

81

32

392

  Mean LVEF,% (range)

62 (50–83)

62 (50–83)

63 (52–79)

62 (50–83)

Study completion, n

509

81

33

395

 Patients who did not complete

486 (95.5)

74 (91.4)

32 (97.0)

380 (96.2)

 Mitoxantrone treatment,b n (%)

    

  Did not complete 5-year study,c n (%)

320 (62.9)

46 (56.8)

27 (81.8)

247 (62.5)

  Completed 5-year study,c n (%)

166 (32.6)

28 (34.6)

5 (15.2)

133 (33.7)

 Patients who completed

23 (4.5)

7 (8.6)

1 (3.0)

15 (3.8)

 Mitoxantrone treatment,b n (%)

  Did not complete 5-year study,c n (%)

17 (3.3)

5 (6.2)

1 (3.0)

11 (2.8)

  Completed 5-year study,c n (%)

6 (1.2)

2 (2.5)

0 (0)

4 (1.0)

  1. EDSS=Expanded Disability Status Scale; LVEF=left ventricular ejection fraction;MS=multiple sclerosis; PRMS=progressive relapsing multiple sclerosis; RENEW=Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis; RRMS=relapsing remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis.
  2. aPatients with validated data who have received at least one dose of Mitoxantrone.
  3. bPatients reaching a cumulative dose of 132 mg/m2 or greater are considered to have completed treatment.
  4. cPatients participating in the study for 5 years ± 3 months are considered to have completed RENEW.